Initiation with Inhaled Long-Acting Anti-Muscarinic Agent (LAMA) Is Associated with Lower Medical Cost and HCRU Compared to Combination of Inhaled Corticosteroid and Long-Acting Beta-Agonists (ICS/LABA) in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Long-Term Real-World Study